Uniphar Group PLC (UPR) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Uniphar Group PLC €3.54, price €4.03, upside -12.1%, quality 52 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Uniphar Group PLC for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range €1.93 – €4.96 · fair‑value band €2.11 – €4.60 · the €4.03 price screens above the €3.54 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.
Follow Uniphar Group in your weekly email
Every Wednesday you see whether Uniphar Group is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Uniphar plc, together with its subsidiaries, operates as a diversified healthcare services company in the Republic of Ireland, the United Kingdom, the Netherlands, and internationally. It operates through three divisions: Uniphar Medtech, Uniphar Pharma, and Uniphar Supply Chain & Retail.
Show more
Uniphar plc, together with its subsidiaries, operates as a diversified healthcare services company in the Republic of Ireland, the United Kingdom, the Netherlands, and internationally. It operates through three divisions: Uniphar Medtech, Uniphar Pharma, and Uniphar Supply Chain & Retail. The company provides sales, marketing, servicing, quality, compliance, regulatory support, and distribution services to medical device manufacturers; high-value services across the life cycle of a pharmaceutical product; and healthcare professionals with access to medicines that cannot source through traditional channels. It is also involved in the pre-wholesale and wholesale distribution of pharmaceutical, healthcare, and animal health products to pharmacies, hospitals and veterinary surgeons; operates a network of pharmacies under the Life, Allcare, Hickey's, and McCauley brands. In addition, the company provides pharmacy support, pharmaceutical supply chain and services, medical device distribution, specialist nursing and infusion, outsourcing and resourcing, healthcare technology, medical affairs, online pharmacy and product fostering, pharmaceutical wholesale distributor, retail pharmacy software and technology, and telecommunications support services, as well as specialist provider of pharmaceuticals. Uniphar plc was founded in 1967 and is headquartered in Dublin, Ireland.
Stock analysis
Uniphar Group PLC (UPR) currently trades at €4.03, while our model-based Fair Value estimate is €3.54, implying the stock looks roughly 13.7% overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of €3.92 per share, and 9 of the 26 models we run sit above the €4.03 price.
Bear case: the Asset-Based group reads lowest at €1.05, and 17 of the 26 models stay below the price. Evidence for this calculation is high.
Scenario range: €2.11 (bear) to €4.60 (bull), the price of €4.03 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 52/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Uniphar Group PLC reported revenue of €3.1B in FY2025 versus €1.9B in FY2021, a compound +12.2%/yr. Reported net income was €51.1M in FY2025, compounding +1.5%/yr from FY2021.
Key figures
Market cap €1.3B · P/E ratio 21.2 · P/S ratio 0.35 · EPS (TTM) €0.1900 · Dividend yield 0.5% · Net margin 1.7% · Return on equity 12.7% · Return on assets (EBIT) 5.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (medium confidence).
What moves the price
The share trades about 18% below its 52-week high and 18% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at −12%, UPR screens richer than that median.
Fair Value models
Bear €2.11Fair Value €3.54Bull €4.60
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (€0.1244 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.83/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+11.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.0%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.1%
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+11.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year+11.4%
Dividend (yield on the price)0.5%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.11% vs 25%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.3% → 3%
Start year 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+22.6%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+4.3%
Yearly sales growth analysts expect, extended to five years.
After inflation (euro area: IMF forecast 2.2% a year to 2030, 2.6% from 2016 to 2025) that is about +20.0% a year for the price and +2.1% for the forecasts.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Distribution · 81 stocks
Beats the industry median on 5/13 measures
Overall it trails its industry peers.
Valuation
Quality Score52 · Above median
Fair Value upside−14% · Below median
Profitability
Return on equity (TTM)13% · Top 25%
Return on assets4% · Above median
Net margin (TTM)2% · Above median
Operating margin (TTM)3% · Below median
Growth and dividend
Revenue growth13% · Top 25%
Dividend yield (TTM)0.5% · Bottom 25%
Balance sheet
Debt / equity0.88× · Highest 25%
Valuation Multiplesvs Medical Distribution median · lower = cheaper
P/E (TTM)21.2× · Pricier than median
P/B3.54× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Uniphar Group PLC Fair Value". https://www.fairvalue-calculator.com/stock/UPR
Frequently asked questions
Is Uniphar Group PLC (UPR) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of €3.54 versus a price of €4.03, about −12% upside (overvalued).
What is the fair value of UPR?
Our model-based fair value for Uniphar Group PLC is €3.54 (as of Sep 23, 2026), built from audited fundamentals. The current price: €4.03.
What is the quality score of UPR?
Uniphar Group PLC has a Quality Score of 52/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Uniphar Group PLC (UPR)?
Our model-based price target is the fair value of €3.54 (as of Sep 23, 2026) from 26 valuation models. Cautious scenario €2.11, optimistic scenario €4.60. It is a calculation from audited fundamentals, not an analyst target.
What is the Uniphar Group PLC stock forecast for 2026?
Our models put fair value at €3.54, about −12% upside versus a price of €4.03 (overvalued). Cautious scenario €2.11, optimistic scenario €4.60. The calculation is refreshed regularly with new filings.
What is the revenue of Uniphar Group PLC (UPR)?
Uniphar Group PLC reported trailing-twelve-month revenue of about €3.1B (latest available figure, as of Sep 23, 2026).
Does Uniphar Group PLC pay a dividend?
Uniphar Group PLC currently shows a dividend yield of about 0.50% relative to its recent price (as of Sep 23, 2026).
What growth is priced into Uniphar Group PLC (UPR)?
For today's price to be fair in a discounted-cash-flow model, Uniphar Group PLC would have to grow free cash flow by +22.6 % per year for five years (discount rate 12.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +11.0 % per year. As of Sep 23, 2026.
What discount rate (WACC) does the fair value of UPR use?
Our models discount Uniphar Group PLC at 12.1 %: a base by market capitalisation (small), damped by beta 1.11, country premium for Ireland. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Uniphar Group PLC that is +22.6 % per year a year over ten years, using the same discount rate (12.1 %) and the same formula as our fair value.
How much growth has Uniphar Group PLC (UPR) delivered so far?
Over the past 5 years revenue at Uniphar Group PLC grew +11.0 % a year. The price currently implies +22.6 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Uniphar Group PLC (UPR) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Uniphar Group PLC (+22.6 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Uniphar Group PLC (UPR)?
The free-cash-flow yield on the price is 4.37 %: that much free cash flow Uniphar Group PLC produces per unit of market value. When it exceeds the discount rate of our models (12.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Uniphar Group PLC (UPR)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Uniphar Group PLC it is €3.54 per share (as of Sep 23, 2026), against a price of €4.03. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Uniphar Group PLC stock overvalued or undervalued in 2026?
As of Sep 23, 2026, UPR trades above its calculated fair value: price €4.03, fair value €3.54, a gap of about −12% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of UPR?
No. The price is what the market pays today (€4.03); the fair value is what the company's own numbers justify (€3.54). For Uniphar Group PLC the two are €0.4850 per share apart. That gap is exactly why we show both numbers side by side.
How much is Uniphar Group PLC worth?
The market values Uniphar Group PLC at about €1.3B (market capitalisation, as of Sep 23, 2026). Per share that is €4.03; our models calculate a fair value of €3.54 per share.
What do the bullish and bearish scenarios say about UPR?
Our models span a range for Uniphar Group PLC: cautious scenario €2.11, base €3.54, optimistic €4.60 per share (as of Sep 23, 2026, price €4.03). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of UPR?
Uniphar Group PLC trades at a price-to-earnings ratio of 21.2 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of €3.54 is built from several models across several years. Other multiples: P/B 3.5, P/S 0.5, EV/EBITDA 14.9.
How solid is the balance sheet of Uniphar Group PLC (UPR)?
Balance-sheet figures for Uniphar Group PLC (as of Sep 23, 2026): return on equity 12.7%, debt of 0.88 per unit of equity. They feed the Quality Score of 52/100, which measures business quality independently of the share price.
How far is UPR from its 52-week high?
Uniphar Group PLC trades at €4.03, about 18% below its 52-week high of €4.92 and 18% above the low of €3.42 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of €3.54 is for.
Which stocks are comparable to Uniphar Group PLC?
From the same area (Healthcare) we also value McKesson Corporation, Cencora, Inc, Cardinal Health, Inc, Henry Schein, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Uniphar Group PLC stock attractive at the current price?
The data as of Sep 23, 2026: price €4.03, calculated fair value €3.54 (−12%), Quality Score 52/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of UPR calculated?
We run Uniphar Group PLC through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €3.54, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Uniphar Group PLC itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Uniphar Group PLC (UPR)?
The closing price on Sep 23, 2026 was €4.03. Our model-based fair value is €3.54, about −12% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Uniphar Group PLC right now?
Solid but not exceptional quality (52/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (€2.11 to €4.60) leaves room in how you read the outcome.
Key figures of Uniphar Group PLC
How large is the market capitalisation of Uniphar Group PLC (UPR)?
The market capitalisation of Uniphar Group PLC is €1.3B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Uniphar Group PLC (UPR)?
The price-to-sales ratio of Uniphar Group PLC is 0.35 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Uniphar Group PLC (UPR)?
Earnings per share at Uniphar Group PLC are €0.1900 (price ÷ EPS = P/E 21.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Uniphar Group PLC (UPR)?
The dividend yield of Uniphar Group PLC is 0.5% (payout 10.5%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Uniphar Group PLC (UPR)?
The net margin of Uniphar Group PLC is 1.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Uniphar Group PLC (UPR)?
The return on equity (ROE) of Uniphar Group PLC is 12.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Uniphar Group PLC (UPR)?
On an EBIT basis the return on assets of Uniphar Group PLC is 5.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Uniphar Group PLC (UPR)?
The operating margin of Uniphar Group PLC is 3.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Uniphar Group PLC (UPR)?
Revenue at Uniphar Group PLC is growing +13.3% versus a year earlier (3y avg +14.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Uniphar Group PLC (UPR)?
Earnings per share at Uniphar Group PLC are growing −27.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Uniphar Group PLC (UPR) carry?
The net debt of Uniphar Group PLC is €171M (fiscal year 2025, ≈ 3.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Uniphar Group PLC in the live analysis
One click puts Uniphar Group PLC on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
